Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade

被引:4
作者
Beatrici, Edoardo [1 ,2 ,3 ,4 ]
Filipas, Dejan K. [2 ,3 ,5 ]
Stone, Benjamin, V [2 ,3 ]
Labban, Muhieddine [2 ,3 ]
Qian, Zhiyu [2 ,3 ]
Lipsitz, Stuart R. [2 ,3 ,6 ]
Lughezzani, Giovanni [1 ,4 ]
Buffi, Nicolo M. [1 ,4 ]
Cole, Alexander P. [2 ,3 ]
Trinh, Quoc-Dien [2 ,3 ]
机构
[1] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[2] Harvard Med Sch, Brigham & Womens Hosp, Div Urol Surg, Boston, MA 02115 USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA
[4] IRCCS, Humanitas Res Hosp, Dept Urol, Milan, Italy
[5] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[6] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA
关键词
COVID-19; Grade; Migration; Prostate cancer; Screening; Stage; DIGITAL RECTAL EXAMINATION; SCREENING TRIAL; OVERTREATMENT; MORTALITY; LUNG; CARE;
D O I
10.1016/j.urolonc.2023.09.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Early 2010s data suggest a reverse stage and grade migration towards more aggressive prostate cancer (PCa) at diagnosis, accelerated by the 2012 US Preventive Services Task Force recommendation against PSA screening. Using the National Cancer Database, we investigated the impact of the 2018 USPSTF recommendation and the COVID-19 outbreak on this shift. We hypothesized that the COVID-19 outbreak would further contribute to a stage and grade migration towards more aggressive disease.Material and methods: We identified men with localized PCa diagnosed between 2010 and 2020. We analyzed the shift in the proportion of PCa stratified according to D'Amico risk classification. We used multivariable logistic regression models to assess the association between year of diagnosis and dichotomous variables related to clinical stage and grade of PCa. Predicted probabilities with 95% CI were computed through marginal effect analyses.Results: We identified 910,898 men with localized PCa. The proportion of low-risk PCa almost halved from 34.9% in 2010 to 17.7% in 2020 (P < 0.001). Compared to 2010, we found in each year increased odds of: PSA >= 10 ng/dL starting from 2012 (aOR2012 1.05; 95% CI, 1.02-1.08); cT3-T4 starting from 2015 (aOR2015 1.10; 95% CI, 1.03-1.17); ISUP GG 3-5 starting from 2011 (aOR2011 1.06; 95% CI, 1.03-1.08); and consequently, D'Amico intermediate/high-risk class starting from 2011 (aOR2011 1.03; 95% CI, 1.01-1.05). Fluctuations in the probabilities of PSA >= 10 ng/dL and cT3-T4 at diagnosis were observed over time (all P < 0.001). The probability of PSA >= 10 ng/dL peaked at 29.0% (95% CI, 28.0%-29.0%) in 2018, while the probability of cT3-T4 peaked at 3.7% (95% CI, 3.6%-3.8%) in 2020. All other outcome variables demonstrated a consistent upward shift (all P < 0.001), with the highest probabilities in 2020 for ISUP GG 3-5 (42.3%, 95% CI, 41.9%-42.6%) and D'Amico intermediate/high-risk (81.3%, 95% CI, 81.0%-81.6%).Conclusions: Our study confirms an enduring shift towards a higher proportion of aggressive PCa at diagnosis, likely influenced by the COVID-19 pandemic. The impact of the 2018 USPSTF PCa screening recommendation on the proportion of aggressive PCa seems restricted and likely affected by the pandemic outbreak. Future investigations should evaluate the long-term effects of the 2018 USPSTF recommendations in the postpandemic setting.(c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:483.e11 / 483.e19
页数:9
相关论文
共 28 条
  • [1] Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
    Ahmed, Hashim U.
    Bosaily, Ahmed El-Shater
    Brown, Louise C.
    Gabe, Rhian
    Kaplan, Richard
    Parmar, Mahesh K.
    Collaco-Moraes, Yolanda
    Ward, Katie
    Hindley, Richard G.
    Freeman, Alex
    Kirkham, Alex P.
    Oldroyd, Robert
    Parker, Chris
    Emberton, Mark
    [J]. LANCET, 2017, 389 (10071) : 815 - 822
  • [2] Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States
    Aizer, Ayal A.
    Gu, Xiangmei
    Chen, Ming-Hui
    Choueiri, Toni K.
    Martin, Neil E.
    Efstathiou, Jason A.
    Hyatt, Andrew S.
    Graham, Powell L.
    Trinh, Quoc-Dien
    Hu, Jim C.
    Nguyen, Paul L.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (01): : 61 - 68
  • [3] Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
    Andriole, Gerald L.
    Crawford, E. David
    Grubb, Robert L., III
    Buys, Saundra S.
    Chia, David
    Church, Timothy R.
    Fouad, Mona N.
    Isaacs, Claudine
    Kvale, Paul A.
    Reding, Douglas J.
    Weissfeld, Joel L.
    Yokochi, Lance A.
    O'Brien, Barbara
    Ragard, Lawrence R.
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hsing, Ann W.
    Izmirlian, Grant
    Pinsky, Paul F.
    Kramer, Barnett S.
    Miller, Anthony B.
    Gohagan, John K.
    Prorok, Philip C.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (02) : 125 - 132
  • [4] Multiparametric MRI - local staging of prostate cancer and beyond
    Caglic, Iztok
    Kovac, Viljem
    Barrett, Tristan
    [J]. RADIOLOGY AND ONCOLOGY, 2019, 53 (02) : 159 - 170
  • [5] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    D'Amico, AV
    Whittington, R
    Malkowicz, SB
    Schultz, D
    Blank, K
    Broderick, GA
    Tomaszewski, JE
    Renshaw, AA
    Kaplan, I
    Beard, CJ
    Wein, A
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
  • [6] Fair Allocation of Scarce Medical Resources in the Time of Covid-19
    Emanuel, Ezekiel J.
    Persad, Govind
    Upshur, Ross
    Thome, Beatriz
    Parker, Michael
    Glickman, Aaron
    Zhang, Cathy
    Boyle, Connor
    Smith, Maxwell
    Phillips, James P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (21) : 2049 - 2055
  • [7] Prostate-Specific Antigen-Based Screening for Prostate Cancer Evidence Report and Systematic Review for the US Preventive Services Task Force
    Fenton, Joshua J.
    Weyrich, Meghan S.
    Durbin, Shauna
    Liu, Yu
    Bang, Heejung
    Melnikow, Joy
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (18): : 1914 - 1931
  • [8] The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA
    Fleshner, Katherine
    Carlsson, Sigrid V.
    Roobol, Monique J.
    [J]. NATURE REVIEWS UROLOGY, 2017, 14 (01) : 26 - 37
  • [9] Contemporary national trends in prostate cancer risk profile at diagnosis
    Fletcher, Sean A.
    Von Landenberg, Nicolas
    Cole, Alexander P.
    Gild, Philipp
    Choueiri, Toni K.
    Lipsitz, Stuart R.
    Trinh, Quoc-Dien
    Kibel, Adam S.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (01) : 81 - 87
  • [10] The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status
    Gohagan, JK
    Prorok, PC
    Hayes, RB
    Kramer, BS
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 251S - 272S